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Summary. Efforts to personalize medicine in oncology have been limited by reductive characterizations of the intrinsically
complex underlying biological phenomena. Future advances in personalized medicine will rely on molecular signatures that
derive from synthesis of multifarious interdependent molecular quantities requiring robust quantitative methods. However,
highly parameterized statistical models when applied in these settings often require a prohibitively large database and are
sensitive to proper characterizations of the treatment-by-covariate interactions, which in practice are difficult to specify and
may be limited by generalized linear models. In this article, we present a Bayesian predictive framework that enables the
integration of a high-dimensional set of genomic features with clinical responses and treatment histories of historical patients,
providing a probabilistic basis for using the clinical and molecular information to personalize therapy for future patients. Our
work represents one of the first attempts to define personalized treatment assignment rules based on large-scale genomic data.
We use actual gene expression data acquired from The Cancer Genome Atlas in the settings of leukemia and glioma to explore
the statistical properties of our proposed Bayesian approach for personalizing treatment selection. The method is shown to
yield considerable improvements in predictive accuracy when compared to penalized regression approaches.
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1. Introduction
Cancer is a complex, dynamic microevolutionary process. It
was the cause of more than 580 thousand deaths in the US
alone in 2013, and has remained the second leading cause
of death for more than half a century (http://www.cdc.gov/
nchs/fastats/leading-causes-of-death.htm). Effective treat-
ment requires an understanding of the alterations within cell
signaling pathways that enable cancer cells to evade routine
cell death and to proliferate and migrate (Alberts et al.,
2002). Variations in the genomes of cancer patients and
among cancer cells within the same tumor make the disease
inherently heterogeneous (Bedard et al., 2013). The study
of individual candidate genes, signaling pathways, behaviors,
or environmental exposures in lieu of better approximations
of the intrinsically complex biological phenomena has lim-
ited our understanding of many areas of oncology (Knox,
2010). For example, after nearly two decades of biomarker
investigations in colorectal cancer, only one biomarker
has been sufficiently validated to warrant its inclusion in
clinical practice: KRAS gene mutations that are predictive
of resistance to anti-EGFR therapy in metastatic disease
(Deschoolmeester et al., 2010). In fact, final market approval
was achieved for 6.7% of new cancer agents that initiated
clinical testing from 2003 to 2011 (Hay et al., 2014).
Many conventional statistical methods assume that pa-
tients are exchangeable within a few disparate biomarker/
mutation subtypes, which fails to account for potential
subsets within the putative marker cohorts (Maitournam
and Simon, 2005; Lee et al., 2010; Kim et al., 2011). Other
methods accommodate patient heterogeneity through co-
variate adjustment Zang et al., 2012; Kang, Janes, and
Huang, 2014. These existing methods require assumptions
for characterizing treatment-by-covariate interactions, which
in practice are difficult to specify and may be limited by gen-
eralized linear models. Future breakthroughs in personalized
medicine will rely on molecular signatures derived from the
synthesis of multifarious interdependent molecular quantities
that will require more advanced quantitative methods.
Moreover, because each tumor is unique, patients should
not be considered statistically “exchangeable.” Rather, the
extent to which results from previously treated patients
inform our expectation of treatment success for a future
patient should depend upon our current understanding of the
extent to which each new patient’s tumor exhibits similarity
with the tumors of the previously treated patients.
In this article, we introduce a utility-based Bayesian pre-
dictive framework that enables personalized treatment selec-
tion for new patients based on the treatment histories and
molecular measurements of previously treated patients. The
proposed approach involves the three sequential components
illustrated in Figure 1. First, we use unsupervised cluster-
ing to quantify the relative molecular similarity between any
two patients in the presence of the available molecular infor-
mation acquired for all patients. Second, we use the molec-
ular similarity measure to characterize the extent to which
each historical patient is partially informative in relation to
each new, heretofore untreated patient. Then we use a utility-
based Bayesian model to combine the clinical responses and
treatment histories of historical patients with the similarity
measures for each new patient, providing a probabilistic ba-
© 2015, The International Biometric Society 1
2 Biometrics
Figure 1. The proposed process for personalizing treatment based on genomic data using Bayesian predictive modeling. Left
box, quantifying the relative molecular similarities among all patients by applying unsupervised clustering methods to genomic
data; middle box, characterizing the extent to which each historical patient should be considered partially exchangeable with
the new patient based on the measure of relative molecular similarity; right box, treatment selection using a Bayesian prediction
model that integrates the genomic similarity measures with the clinical information, which in this case consists of ordinal
outcomes based on the Response Evaluation Criteria In Solid Tumors (RECIST): progressive disease (PD), stable disease
(SD), partial response (PR), and complete response (CR). Treatment 2 (T2) obtains higher predictive utility value, and
therefore is recommended for the new patient.
sis for using the clinical and molecular information acquired
from each historical patient to predict each new patient’s per-
sonalized treatment utility under each candidate therapy. Our
approach relies on a heuristic measure of molecular similarity,
which provides robustness to the underlying stochastic data
model and feasibility in the presence of a small sample.
The ideas in this article are conveyed in the following
sequence. In Section 2, we present the Bayesian predictive
method for personalized treatment selection. In Section 3,
we use simulations to evaluate the method’s capacity to
learn from accumulating information in the presence of com-
plex predictive relationships between molecular quantities and
treatment response. In Section 4, we demonstrate the po-
tential clinical utility of our personalized treatment strategy
when applied to a data set of lower grade glioma obtained
from The Cancer Genome Atlas (TCGA). We provide con-
cluding remarks in Section 5.
2. Method
We assume that patients who have tumors that are molecu-
larly similar are partially exchangeable, and hence avoid con-
ducting inference on a potentially complex but misspecified
model for the treatment-covariate interactions. Our modeling
approach involves two steps. In the first step, we apply un-
supervised clustering to generate similarity measures based
on the genomic covariates. In the second step, we integrate
the similarity measures into a Bayesian model that we use to
compute the personalized predictive utility of each candidate
treatment. There is a very rich body of literature on the use
of clustering algorithms and techniques in different scientific
disciplines (Jain, 2010). We briefly introduce two methods
commonly used in oncology in Section 2.1, and present the
Bayesian predictive model in Section 2.2. In Section 2.3, we
demonstrate how to compute a personalized predictive treat-
ment utility.
2.1. Quantifying Tumor Similarity between Patients
Using Unsupervised Clustering
Using the available methods for unsupervised clustering, we
can quantify molecular similarities among tumors in relation
to the available genomic information provided by previously
treated patients. Several studies have shown that clustering
approaches based on multiple genes can successfully predict
clinical outcomes (Fan et al., 2006), whereas methods based
on a small set of genes may not fully characterize tumor het-
erogeneity (Kelloff and Sigman, 2012). Importantly, other re-
cent studies have confirmed that molecular subtypes defined
by clustering methods were associated with clinical endpoints
(Sadanandam et al., 2013). However, because different clus-
tering algorithms may result in different partitions of the
same data set (Jain, 2010), these methods may yield different
patient-cluster assignments. This undesirable scenario occurs
frequently when the relevant characteristics of some patients
lie near the boundaries between two or more groups (Lai et al.,
2013). Consequently, subgroup analyses that use groups de-
fined by clusters are limited in this context because they ig-
nore intra-group heterogeneity.
To overcome this issue, our prediction model incorporates
a continuous measure of similarity that assumes a value on
the unit interval [0, 1]. The similarity measure quantifies the
extent to which the tumors from any two patients may be con-
sidered similar based on the current understanding of the ex-
tent of heterogeneity exhibited by the disease. In Section 2.2,
we propose a statistical model for predicting the treatment
response of each new patient that assigns a higher weight to
information contributed by historical patients whose tumors
exhibit greater similarity. At the boundaries, patients who
attain similarity 1 are assumed to be statistically exchange-
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able, while the treatment histories for patients with similarity
measure 0 fail to inform the prediction.
We consider a data set consisting of l biomarkers in n pa-
tients, denoted by Xl×n. Without loss of generality, we treat
these biomarkers as continuous variables, such as gene or
protein expression levels. We derive the pairwise similarities
from clustering methods based on Xl×n and store them in
the n × n symmetric similarity matrix S. Two widely applied
approaches, consensus clustering (CC) (Monti et al., 2003)
and nonnegative matrix factorization (NMF) (Brunet et al.,
2004), are explored in our simulation and case studies. More
details of these two methods are provided in Section A of the
Supplementary Materials.
2.2. Bayesian Predictive Model for Partially
Exchangeable Data
Let j = 1, . . . , J index candidate therapies in a training data
set consisting of data from n =∑J
j=1 nj patients, where nj de-
notes the number of patients treated with therapy j. We as-
sume that the therapeutic response to the treatment (e.g., tu-
mor response), evaluated via an ordinal-valued criteria (such
as the commonly utilized response criteria described in the
next section) has been ascertained and that baseline molecular
characteristics have been measured for each patient. Let yi de-
note the random variable of the ith patient’s response to ther-
apy Ai = j among K possible levels of increasing treatment
benefit, where yi = k, for i = 1, . . . , n, and k = 0, 1, . . . , K − 1.
In addition, let θj = {πj,k : k = 0, 1, 2, . . . , K − 1}, denote the
model parameters associated with the jth therapy, where πj,k
characterizes the probability of observing outcome k under
treatment j. Let θ = {θj : j = 0, 1, 2, . . . , J} denote the collec-
tion of all model parameters. As the treatment response is
represented by an ordinal value, yi follows a multinomial dis-
tribution yi|Ai = j ∼ Multinomial(θj). We devise a personal-
ized treatment rule for the purpose of selecting a therapy
for a newly enrolled, untreated patient on the basis of the
treatment histories of previously treated patients. Thus, sta-
tistically, the selection rules should derive from statements
of predictive probability which accounts for both the uncer-
tainty arising from estimation of the model parameters using
the historical information and the extent of variability in as-
certaining the responses of future patients. Let i˜ index a new,
heretofore untreated patient. Given the observed responses
for the nj patients previously treated with therapy j, which
we denote by Y j, we represent the predictive probability of
response level k under treatment j as
Pr(y˜i = k|Y j, Ai˜ = j, x˜i), (1)
where x˜i denotes the l-dimensional vector containing measure-
ments from l molecular biomarkers for the i˜th patient. Note
that (1) also depends on the biomarker measures Xl×n for all
previously treated patients, which we omit to simplify the
notation.
We proceed to derive (1) using a Bayesian model, whereby
the extent to which two patients are considered exchange-
able is determined by the similarity measure. This can be
achieved using a power prior model. A power prior represents
a “weighted” Bayesian update of an “initial prior” p(θ) us-
ing a supplemental data source, D0, for inference on a pri-
mary data source D (Ibrahim et al., 2003). In our setting,
D0 = {Y ,X} represents the data for all historically treated
patients, and the primary data source is D = {y˜i, x˜i}. Let
L(θ|·) denote the likelihood function, assumed to be com-
mon for both data sources. Formally under the power prior
formulation, the posterior distribution of θ|D,D0 arises as
p(θ|D,D0) ∝ L(θ|D)L(θ|D0)a0p(θ), where the exponent, a0 ∈
[0, 1], controls the extent to which the supplemental data
influence the posterior. Because the likelihood functions for
the supplemental and primary data sources assume identical
model parameters, θ, formally a0 can be interpreted as a mea-
sure of the extent to which D0 is “exchangeable” with D.
Recall that the (r, i)th entry of the similarity matrix, S,
represents the pairwise similarity measure between patients r
and i. In order to identify the best therapy for the new pa-
tient, we use the power prior framework to combine the ob-
served treatment outcomes with the pairwise similarity mea-
sures for the new patient, {S(˜i, 1), y1}, . . . , {S(˜i, n), yn}, to
compute the predictive probability of treatment success un-
der each candidate therapy. Specifically, we use the pairwise
similarity measures as exponents, a0, and thereby assume that
the similarity measures characterize the extent to which each
historical patient is statistically exchangeable with the new
patient. Assuming independent Dirichlet(αj) “initial priors”
for each therapy, j = 1, ..., J, where we choose hyperparam-
eters αj = {αj,k : k = 0, 1, 2, . . . , K − 1} for model parameters
θj = {πj,k : k = 0, 1, 2, . . . , K − 1}, the posterior distribution is
p(θj|Y j, y˜i) ∝ L(θj|y˜i)
{
nj∏
i=1
L(θj|yi)S(˜i,i)
}
p(θj). (2)
The index j indicates that data from all patients previ-
ously treated with therapy j is utilized when constructing
the treatment-specific power priors. To simplify the notation,
we assume that data for patients assigned treatment j are of
the order S(˜i, 1), . . . , S(˜i, nj).
For treatment selection, we are interested in the predictive
probability of y˜i = k, (1), which derives from the integration
of (2) with respect to θj. The posterior predictive distribution
of (y˜i|Y j, Ai˜ = j, x˜i) is given as
p(y˜i|Y j, Ai˜ = j, x˜i) =
∫
L(θj|y˜i, Ai˜ = j)
×
{∏
L(θj|yi)S(˜i,i)
}
p(θj)dθj. (3)
Defining the indicator Ik(yi) = 1 if yi = k and 0 otherwise, we
can simplify the power prior as:
{∏nj
i=1 L(θj|yi)S(˜i,i)
}
p(θj) ∝∏K−1
k=0 (πj,k)
{∑nj
i=1 S(˜i,i)Ik(yi)+αjk−1
}
. Recognizing that∏K−1
k=0 (πj,k)
{∑nj
i=1 S(˜i,i)Ik(yi)+αjk−1
}
is the kernel of a
Dirichlet(α˜j) distribution, with α˜j={α˜j,k : k=0, 1, 2, . . . , K−1}
and α˜jk =
∑nj
i=1 S(˜i, i)Ik(yi) + αjk, the power prior is
{
nj∏
i=1
L(θj|yi)S(˜i,i)
}
p(θj)
= (
∑K−1
k=0 α˜jk)∏K−1
k=0 (α˜jk)
K−1∏
k=0
(πj,k)
{∑nj
i=1 S(˜i,i)Ik(yi)+αjk−1
}
. (4)
4 Biometrics
Thus, we can express the predictive density (3) as follows:
p(y˜i|Y j, Ai˜ = j, x˜i)
= (
∑K−1
k=0 α˜jk)∏K−1
k=0 (α˜jk)
∫ ∫
. . .
∫
L(πj,1, πj,2, . . . , πj,K|y˜i, Ai˜ = j)
×
K−1∏
k=0
(πj,k)
α˜jk dπj,1, dπj,2, . . . , dπj,K−1.
Therefore, the power prior predictive probability of y˜i = k (1)
is
p(y˜i = k|Y j, Ai˜=j, x˜i)=E(πj,k|α˜j1, α˜j2, . . . , α˜jK) =
α˜jk∑K−1
k=0 α˜jk
.
(5)
Note that the total “prior effective sample size” (or amount of
effective information contained in the prior when character-
ized as a sample size) for predicting the new patient’s treat-
ment outcome is
∑K−1
k=0 α˜jk, and thus depends on the extent to
which the new patient’s tumor exhibits similarity with those
of the previously treated patients.
In addition, (5) provides the predictive probability of treat-
ment success for the special case of binary outcomes. Thus,
among the J candidate therapies, the one with the maximum
predictive probability would be recommended. However, this
strategy is limited when used for treatment selection in set-
tings with multinomial response categories (e.g., short-term
tumor response).
2.3. Personalized Predictive Treatment Utility
In this section, we consider how to proceed with treatment
selection in a multinomial setting, where we use utilities
to obtain an one-dimensional selection criterion. In clini-
cal oncology, often there are multiple therapeutic objectives
that pertain to the extent of loco-regional control of a tu-
mor, distant tumor progression, and the occurrence of tox-
icity. Short-term “surrogate” endpoints, such as “objective
tumor response,” are most commonly used in lieu of long-
term progression-free or overall survival durations, which rep-
resent the primary therapeutic endpoints for demonstrating
clinical benefit (FDA, 2007). Tumor response can be ob-
served shortly after treatment, for example, using RECIST
(http://www.recist.com/), which considers both changes in
tumor size as well as the occurrence of new lesions and/or
distant migration (Michaelis and Ratain, 2006). According to
RECIST, the four ordinal tumor response categories are pro-
gressive disease (PD), stable disease (SD), partial response
(PR), and complete response (CR). Decisions pertaining to
treatment selection in this multinomial setting need consider
the relative importance of each level of the ordinal response.
Section B of the Supplementary Materials describes other
types of ordinal-valued response criteria that are commonly
utilized in oncology.
We can establish utility weights by considering the relation-
ship between tumor response and the primary therapeutic
goal (e.g., overall survival), whereby the utilities define the
extent to which each short-term response level achieves the
clinical objectives. Let wk denote the utility assigned to tumor
response level k. Section D.2 of the Supplementary Materials
describes strategies for specifying the utilities in the presence
of historical data. Given these weights, we can calculate the
mean “predictive utility” of treatment j for patient i˜ as
μj (˜i) =
K−1∑
k=0
wk × p(y˜i = k|Y j, Ai˜ = j, x˜i). (6)
We assign to patient i˜ the treatment with the largest predic-
tive utility, which may be considered as “optimal” among the
available therapies given the current information.
3. Simulation Study
We used simulation to evaluate the performance of the pro-
posed method for personalized treatment selection. Our sim-
ulation study was based on actual gene expression data from
a well-known data set of leukemia, which we describe in Sec-
tion C.1 of the Supplementary Materials. We simulated the
application of NMF as well as CC with hierarchical (HC),
k-means (KM) and partitioning around medoids (PAM) al-
gorithms (Gaujoux and Seoighe, 2010; Wilkerson and Hayes,
2010). Hereafter, we refer to these methods as NMF, HC,
KM, and PAM. We compared the performance of our methods
to that of commensurate treatment selection rules obtained
from three competing approaches: an unweighted version of
our Bayesian predictive approach that assumes all patients
are exchangeable, the L1 penalized continuation ratio model
(or Lasso), and ridge regression (Archer and Williams, 2012).
After fitting separate models for each treatment group, per-
sonalized treatments were selected to maximize the resulting
predicted utility. Identical response utility weights were used
for all methods.
3.1. Simulation Approach
Simulation scenarios. We considered two treatments under
three scenarios. In scenario 1, treatment 1 was generally more
beneficial for ALL (patients 1–27), while treatment 2 targeted
AML (patients 28–38). We determined the response probabil-
ities for scenario 1 from the linear combination of two meta-
genes obtained from NMF with rank 2. Scenario 2 mimicked
scenario 1; however, we used the first principal component ob-
tained from PCA to determine the response probabilities. In
scenario 2, the true response probabilities for patients 20–27
were slightly better than those for patients 1–19; whereas the
true response probabilities in scenario 1 were roughly similar
for patients 1–27. In scenario 3, we used a linear combina-
tion of the first two principal components. For this scenario,
treatment 1 was effective for all patients, with the exception
of patients 20–27, who benefited from treatment 2. Details
pertaining to the simulation design are provided in Section
C.2 of the Supplementary Materials.
For all methods and scenarios, we fixed the response util-
ity weights at w0 = 0, w1 = 20, w2 = 60, and w3 = 100 to re-
flect conventional tumor response criteria based on PD, SD,
PR, and CR, respectively. After specifying the true parame-
ters of the generating model for each simulation scenario, we
used the resulting response probabilities P(yi = k|xi, Ai = j)
to calculate the true mean treatment utility (MTU) for
patient i with treatment j, which we denote hereafter by
MTU(i, j) =∑
k
wkP(yi = k|xi, Ai = j). Figure S1 in Section
C.3 of the Supplementary Materials depicts the true differ-
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ences in the MTUs, MTU(i)=MTU(i, 1)−MTU(i, 2), that
result for each patient, i = 1, . . . , 38, under each of the three
simulation scenarios. The scenarios reflect the following in-
evitabilities inherent in personalized medicine in oncology: 1)
patients whose cancers exhibit molecular similarity may bene-
fit (or not) from the same treatment; 2) the benefits may vary
largely even among patients classified into the same broad
subgroups; 3) the targeted treatment may yield only minimal
benefit, especially for those “boundary” patients who pos-
sess genomic characteristics intrinsic to both subgroups (e.g.,
note that in scenario 2 the differences in utilities for ALL-B
patients 6 and 11 are close to zero). In the original study,
two patients were misclassified in terms of cancer subtype,
while patient 29 was misclassified in our simulation. Possible
explanations are that these samples were near the boundaries
between clusters or these patients were misdiagnosed (Brunet
et al., 2004). Because we used gene expressions (as opposed
to leukemia subtype) to determine the response probabilities,
patients who were originally misclassified were retained in our
simulation study to evaluate the extent to which the perfor-
mance of the proposed genomic-based method for personal-
ized treatment selection would vary for these patients.
Treatment selection. For each patient, we predicted the
mean utility (6) of each treatment using the observed re-
sponses acquired for the other n = 37 patients. We assigned
patients to the treatment that yielded the highest predicted
mean utility. For each iteration of the simulation, this pro-
cess was repeated until treatments were assigned for all
n = 38 patients for each of the considered methods. The
proposed Bayesian predictive model assumed a flat prior,
θ1, θ2 ∼ Dirichlet(0.25, 0.25, 0.25, 0.25), for the response prob-
ability vector corresponding to each of the two treatments.
For the Lasso and ridge regression methods, we used Akaike’s
information criterion (AIC) to select the best model among
those within a specified range of the penalty parameter λ
(from 0.01 to 1 times λmax, which is the smallest value such
that the coefficients are zero) (Friedman et al., 2010).
Performance evaluation. Because the treatment-
specific mean utilities are known for each patient, we can
compare the simulated treatment assignments to the true
optimal treatment determined by the simulation scenario
for each patient. The average number of patients who were
assigned non-optimal treatments (referred to as CT) provides
a simple measure for comparing the methods. In addition,
because patients are inherently heterogeneous, the extent
to which the optimal treatment provides an improvement
(in relation to the non-optimal treatment) varies for each
patient. Intuitively, treatment selection should be compared
in consideration of the extent to which each assignment
yields differential treatment benefit, which is determined for
each patient by MTU(i). Therefore, we also compared the
various methods on the basis of the extent of gain achieved
by each simulated treatment assignment as measured by
the difference in the true mean treatment utilities (the
assigned minus the non-assigned). To facilitate this compar-
ison, we needed to consider a new summary statistic. Let
j∗(i) = argmaxj
{∑K−1
k=0 wk × P(yi = k|xi, Ai = j)
}
, represent
the true optimal treatment for patient i and let jg(i) denote
the treatment recommended by selection rule g. Letting
indicator A∗
{
jg(i)
} = 1 if jg(i) = j∗(i) and −1 otherwise,
the total MTU that is obtained for any selection rule can be
defined as the sum of true gains (or losses) achieved for each
treatment assignment, MTUg =
∑n
i
A∗
{
jg(i)
} |MTU(i)|.
For each simulation scenario, the maximum possible total
MTU, which we denote by MTUopt =
∑n
i
|MTU(i)|, is
achieved when all patients are assigned to their respective
optimal treatments. We compared the total MTU resulting
from each competing method for treatment selection in
proportion to the maximum possible total MTU, which we
denote by %MTUg = MTUg/MTUopt. Thus, %MTUg
is bounded above by 1, which represents the best possible
simulation result. Larger values of %MTUg imply that rule
g yielded better overall performance for treatment selection.
We generated a total of 100 duplicated data sets to calculate
CT and %MTUg for each of the methods.
3.2. Simulation Results
The proposed Bayesian predictive methods generally outper-
formed the methods based on penalized regression (ridge re-
gression and Lasso), with the exception of PAM in scenarios
1 and 2 (Table 1). Among the Bayesian predictive implemen-
tations, there seems to be no uniformly superior approach for
all scenarios. However, NMF maintained relatively accurate
predictive performance for treatment selection in all scenar-
ios, with HC achieving a close second best performance. In
contrast, PAM worked very well only in scenario 3. Assign-
ments based on the elastic net (Zou and Hastie, 2005) were
also simulated, but effectuated only slight improvement when
compared to Lasso and ride regression (results are provided
in Section C.4 of the Supplementary Materials).
We found consistency between the numbers of patients
assigned to non-optimal treatments (CT) and the results
obtained for %MTUg. For example, PAM (in scenarios 1
and 2), ridge regression and the Lasso method assigned
more patients, on average, to the non-optimal treatment.
Consequently, %MTUg obtained for these approaches were
significantly lower than those of the competing methods.
For instance, in scenario 1 with the top 100 genes, NMF3
achieved the best possible result, with 0 loss in the maximum
mean utility (%MTUg=1); whereas Lasso resulted in a 23%
loss (%MTUg=0.77) on average. This represents a 30%
increase in %MTUg for NMF3 when compared to Lasso.
To clarify the relative performance of each method, we pro-
vide more detailed results for a subset of patients in Table 2.
The top panel in Table 2 displays the results for 10 patients
for whom the smallest differences in the true mean treat-
ment utilities were found. Thus, for these patients, the respec-
tive optimal treatments should be more difficult to determine
from the data. We found that both ridge and Lasso method
frequently assigned patients to the less beneficial treatment
among the cohort of patients for whom the optimal treat-
ment provides limited clinical benefit. In contrast, the NMF-
based approaches assigned the most patients to the optimal
treatments almost uniformly, with the exception of patient
17, for whom the less beneficial treatment was chosen more
than 80 times (out of 100). The results achieved by HC3-5
were similar, with diminished performance for patients 6 and
29. For comparison, NMF3 assigned all of these patients (ex-
cept patient 17) to the less beneficial treatments fewer than
4 times (out of 100); whereas Lasso assigned all patients in
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Table 1
Simulation results for the scenarios portrayed in Figure 2 based on the top 100 and 200 varied genes. %g=%MTUg
represents the average proportion of the maximum possible gain in total MTU. CT represents the average number of patients
who were assigned to non-optimal treatments. We implemented the Bayesian prediction method using four clustering
methods: NMF3–NMF5, HC3–HC5, KM3–KM5, and PAM3–PAM5, which represent the non-negative matrix factorization
method as well as consensus clustering approaches using hierarchical, k-means, and partitioning around medoids algorithms,
with ranks of 3–5, respectively.
Scenario 1 Scenario 2 Scenario 3
Treatment selection 100 Genes 200 Genes 100 Genes 200 Genes 100 Genes 200 Genes
method %g(CT) %g(CT) %g(CT) %g(CT) %g(CT) %g(CT)
Bayesian predictive approach without similarities
0.47 (10.22) 0.15 (13.78) 0.60 (8.00)
Bayesian predictive approach with similarities
NMF3 1.00 (0.00) 1.00 (0.00) 0.93 (1.78) 0.93 (1.86) 0.95 (1.19) 0.95 (1.20)
NMF4 1.00 (0.04) 1.00 (0.01) 0.92 (2.17) 0.92 (2.01) 0.95 (1.22) 0.95 (1.21)
NMF5 0.98 (0.48) 0.96 (1.09) 0.91 (2.48) 0.92 (1.93) 0.93 (1.77) 0.93 (1.66)
HC3 0.91 (3.13) 0.91 (3.01) 0.93 (2.82) 0.92 (2.86) 0.95 (1.19) 0.95 (1.19)
HC4 0.91 (3.08) 0.92 (2,72) 0.93 (2.85) 0.92 (2.97) 0.95 (1.19) 0.95 (1.19)
HC5 0.91 (3.05) 0.93 (2.50) 0.92 (2.93) 0.92 (3.04) 0.95 (1.19) 0.92 (1.75)
KM3 0.74 (5.71) 0.74 (5.80) 0.78 (5.26) 0.76 (5.66) 0.81 (3.74) 0.70 (6.02)
KM4 0.87 (2.88) 0.79 (4.63) 0.88 (3.15) 0.82 (4.38) 0.96 (0.89) 0.91 (2.03)
KM5 0.93 (1.54) 0.93 (1.63) 0.90 (2.61) 0.88 (3.15) 0.97 (0.75) 0.94 (1.38)
PAM3 0.67 (6.88) 0.66 (7.06) 0.61 (8.83) 0.56 (9.51) 0.94 (1.49) 0.92 (1.63)
PAM4 0.73 (5.93) 0.70 (6.40) 0.71 (6.84) 0.65 (7.88) 0.95 (1.24) 0.96 (0.64)
PAM5 0.75 (5.63) 0.75 (5.42) 0.74 (6.30) 0.77 (5.41) 0.95 (1.28) 0.96 (0.64)
Penalized regression
Ridge 0.86 (3.03) 0.88 (3.12) 0.87 (4.02) 0.85 (4.66) 0.88 (3.02) 0.87 (3.13)
Lasso 0.77 (4.94) 0.82 (4.08) 0.66 (8.77) 0.71 (7.40) 0.74 (5.74) 0.73 (5.54)
the top panel to the inferior treatment at least 21 times (with
a range of 21–47). The middle panel of Table 2 presents the
10 patients for whom the largest differences in mean treat-
ment utilities were obtained, and thus for whom the respective
optimal treatment should be easier to identify. We observed
improved treatment selection for these patients under all the
competing approaches. However, ridge and Lasso continued to
show diminished performance when compared to the Bayesian
predictive approaches. For example, NMF3-5 and HC3-5 cor-
rectly assigned patient 33 to the optimal treatment for ev-
ery assignment, while ridge and Lasso assigned this patient
to the less beneficial treatment 7 and 13 times (out of 100),
respectively.
The bottom panel of Table 2 displays the results for the
patient cohort targeted by treatment 2 in scenario 3, with
200 genes. Again, ridge and Lasso assigned patients to less
beneficial treatments more often than the Bayesian predic-
tive approaches. For example, patient 26 was assigned to the
non-optimal treatment 64 and 41 times, respectively. In con-
trast, our proposed Bayesian predictive method using NMF
and HC resulted in only 1 incorrect assignment for this pa-
tient. The poor results for penalized regression approaches
may be explained in part by sensitivity to the small sample
size, which involved only 8 patients for this subgroup. How-
ever, as demonstrated in Section C.5 of the Supplementary
Materials, they did not yield improved results when applied
in an expanded simulation study involving 152 patients, with
40 patients benefiting from treatment 1.
While the Bayesian predictive approach is useful for
treatment selection, its performance does depend on the
chosen clustering algorithm, rank and genomic features.
Section C.3 of the Supplementary Materials presents re-
sults obtained from our full simulation study, wherein we
evaluated performance for ranks 2–10 for all clustering
methods under consideration. The full simulation results are
presented in Table S2. Figures S2 and S3 in Section C.3 of
the Supplementary Materials summarize the distributions of
these summary statistics. In all simulation scenarios, results
for NMF3-9 and HC3-8 (Table S2) are shown to deviate
less from their respective means when compared to results
obtained for the penalized regression approaches. In contrast,
the Bayesian predictive approach based on PAM worked well
only in scenario 3. In addition, the results obtained from the
top 200 genes were quite close to those resulting from the top
100 genes for every scenario. Additionally, as demonstrated in
Section C.5 of the Supplementary Materials, predictive accu-
racy diminishes as more noise is introduced into the genomic
features. Overall, our proposed approach is most beneficial in
contexts wherein patient similarity is measured in relation to
a set of pre-specified candidate molecular features that have
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Table 2
Number of non-optimal treatment assignments among 100 replications of the simulation under scenarios 2 and 3, with 200
genes for a subset of selected patients. NMF3–NMF5 and HC3–HC5 represent the non-negative matrix factorization method
and consensus clustering approach using a hierarchical algorithm, with ranks of 3–5, respectively. MTU provides the
patient-specific true difference in mean treatment utility, where positive (negative) values favor treatment 1 (treatment 2).
Bayesian predictive Penalized regression
Subject MTU NMF3 NMF4 NMF5 HC3 HC4 HC5 Ridge Lasso
Scenario 2 with 200 genes
Top 10 patients with least differences in mean treatment utility
20 1.4 0 0 0 0 0 0 40 40
11 3.2 2 5 7 4 5 10 33 28
6 4.2 4 2 9 98 99 97 43 37
32 −9.5 2 1 4 0 2 1 27 27
10 9.6 0 0 0 0 0 0 19 26
17 −13.3 96 86 11 4 10 14 49 47
29 13.3 4 6 17 100 99 99 23 37
3 13.7 4 6 7 5 4 3 6 21
13 15.9 3 4 6 5 4 4 25 29
7 17.3 3 5 8 4 4 4 13 36
Top 10 patients with largest differences in mean treatment utility
33 −37.3 0 0 0 0 0 0 7 13
22 40.8 2 2 2 2 2 2 4 7
23 43.5 0 0 0 0 0 0 5 15
25 43.9 0 0 0 0 0 0 1 7
21 45.7 0 0 0 0 0 0 1 6
27 46.3 0 0 0 0 0 0 1 5
38 −54.5 2 2 1 2 2 3 3 12
35 −56.8 4 4 2 1 3 3 1 5
31 −59.4 3 3 1 1 2 2 9 5
30 −63.0 3 3 1 2 2 2 1 1
Scenario 3 with 200 genes
All patients who benefit from treatment 2
20 −12.5 1 1 1 1 1 1 81 45
21 −43.7 2 2 2 2 2 2 3 15
22 −40.5 4 4 4 4 4 4 14 15
23 −42.1 3 3 3 3 3 3 10 19
24 −38.3 7 7 7 7 7 7 20 26
25 −39.5 2 2 2 2 2 2 19 18
26 −26.3 1 1 1 1 1 1 64 41
27 −40.7 1 1 1 1 1 1 28 16
been identified as intrinsic to disease pathogenesis in prior
study.
4. Case Study of Lower Grade Glioma
4.1. TCGA Data
We applied the proposed methods to the publicly available
data of lower grade glioma from the TCGA data portal.
We downloaded both the clinical and level 3 RNASeqV2
mRNA expression data from https://tcga-data.nci.nih.gov/
tcga/tcgaHome2.jsp. Baseline and follow-up information was
collected on 240 patients; 156 (65%) and 136 (57%) patients
who received adjuvant radiation and targeted therapies, re-
spectively. We excluded from the analysis the data for three
patients who had missing values of responses and one who had
no genomic information. We focused on the subset of patients
treated with adjuvant radiation and investigated two treat-
ment regimes, targeted therapies (n = 113) compared to non-
targeted therapies (n = 41). Among the 154 patients in this
analysis, 52 were classified as having grade II glioma (34%)
and 102 as having grade III glioma (66%). We categorized tu-
mor responses into the four standard categories, CR, PR, SD,
and PD. As only 5 patients achieved PR, we combined PR
and CR into a new category of treatment responders, which
we abbreviate as CP. The three levels of the ordinal outcomes
are therefore CP, SD, and PD. Since the TCGA data were
collected from observational studies, we matched 41 pairs of
patients to avoid potential bias. More details pertaining to
the matching procedure and resulting covariate balance can
be found in Section D.1 of the Supplementary Materials.
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4.2. Data Analysis
We calculated the maximum absolute deviation (the maxi-
mum value minus the minimum value) for each gene, selected
the top 200 most varying genes for the analysis, and stan-
dardized the gene expression values. As the RNASeqV2 data
are read counts, which are naturally non-negative, we applied
NMF to the original expression data. As explained in Sec-
tion D.2 of the Supplementary Materials, we fixed the utility
weights as 0, 25, and 100 for PD, SD, and CP, respectively.
Hereafter, we discuss an empirical summary measure that we
use to evaluate the potential clinical impact of our proposed
personalized treatment selection method in this setting.
Summary measures. Following published approaches
(Song and Pepe, 2004; Kang et al., 2014), we assessed model
performance according to the following summary measure,
which can be interpreted as the increased clinical benefit
derived from biomarker-driven treatment selection with re-
spect to randomized treatment assignment. Let R˜ denote the
random treatment response, and define (X) = P(R˜ = 1|A =
1,X) − P(R˜ = 1|A = 0,X) where A = 0, 1 represents the tar-
geted and non-targeted treatments, respectively. The relative
increase in the population response rate under a biomarker-
based treatment selection method in relation to randomized
assignment is defined as
{P(R˜ = 1|A = 1,(X) > 0) × P((X) > 0)
+P(R˜ = 1|A = 0,(X) < 0) × P((X) < 0)} − P(R˜ = 1|A),
which can be estimated from the data (Kang et al., 2014),
i.e., the overall response rate calculated as the number of
responders (CP) divided by the total sample size. We used
the response rates for the subset of patients assigned by the
proposed method (e.g., (X) > 0) to the treatment actually
received (e.g., A = 1) to estimate the extent of clinical benefit
that is attributable to the proposed method (Song and Pepe,
2004). The weight P((X) > 0) can be empirically estimated
as the number of patients who are recommended for targeted
treatment divided by the total number of patients. Quantities
involving A = 0 and (X) < 0 can be similarly calculated.
The difference in the two quantities therefore measures the
increased clinical benefit obtained under a specific treatment
selection method, which we reference hereafter as the “sum-
mary measure.” Note that we based this summary measure
on only two response categories, (CP) and non-responders
(PD+SD); whereas, we used all three levels of the ordinal
outcome in the data analysis and to implement personalized
treatment selection.
4.3. Results
We investigated the performance of the clustering approaches,
implementing cluster ranks of 2–10. The results are presented
in detail in Section D.3 of the Supplementary Materials. The
summary measures for NM2, HC7, KM2, PAM7 were 0.103,
0.187, 0.055, 0.091, respectively. Results obtained from all im-
plementations of HC were noticeably better than those ob-
tained from any of the other approaches we considered. We
also observed that model performances varied by cluster rank.
This was likely caused by discrepancies between cluster as-
signments that result from varying the cluster rank, which
suggests that some implementations fail to identify potential
hidden clusters in the data (Li et al., 2009).
We further conducted leave-one-out cross-validation
(LOOCV) analyses using the summary measure as the cri-
teria for model (rank) selection (Foster et al., 2011; DeRubeis
et al., 2014). We followed the same procedure for the ridge
and Lasso methods, but used AIC for model selection. The
LOOCV based summary measures for NMF, HC, KM, PAM,
ridge regression and Lasso were 0.037, 0.158, −0.002, 0.02,
0.017, and −0.001, respectively. Again, HC yielded the highest
value of the summary measure, and we also found that rank=7
was selected most of the time (35/82). Based on these results,
we would recommend that investigators use the Bayesian pre-
dictive method with HC7 when selecting treatments for future
patients with low grade glioma. Additional discussion pertain-
ing to cluster and rank selection can be found in Section D.4
of the Supplementary Materials.
5. Discussion
In this article, we propose a utility-based Bayesian predic-
tive modeling approach to inform treatment selection. This
method circumvents the need to assume that patients are
fully “exchangeable,” and hence is suitable for highly het-
erogeneous diseases such as cancer. We conducted simulation
studies to evaluate the method’s performance and analyzed
a data set of low grade glioma to illustrate the utility of the
proposed approach. Our analysis of the low grade glioma data
showed that the overall response rate could be, on average,
increased by 15.8% when compared to a default strategy of
randomly allocating patients treatments, if the treatment se-
lection recommendations derived from the Bayesian predic-
tive method with HC7 were followed. Moreover, the proposed
Bayesian predictive approach was shown to outperform the
penalized regression approaches in both the simulation and
case studies. Additional comparisons with selection methods
devised for low-dimensional settings, such as those proposed
by Zhang et al. (2012), could have been considered following
application of dimension reduction techniques (e.g., principal
component analysis).
Our work represents one of the first attempts to define
personalized treatment assignment rules based on large-scale
genomic data. The following criteria should be considered
carefully before implementing the approach in practice: spec-
imen quality, assay procedures, model evaluation, response
criteria, and clinical trial designs (McShane et al., 2013). In
this article, we used data from existing observational studies.
While our simulation study utilized the actual genomic data
to generate patient responses, actual treatment outcomes
were used in the analysis of our case study, wherein analysis
considered a matched subset to attenuate potential selection
bias. Specifically, we matched patients by age, gender, and
tumor grade. However, because bias due to unmeasured
confounding factors cannot be removed, one should use
caution when interpreting the results. The methodology
presented here is perhaps most useful when implemented
with training data that was acquired from randomized study,
and thus devoid of selection bias.
Our model can be easily implemented and is computation-
ally efficient. While the computation time required to obtain a
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similarity measure depends on the data size, clustering meth-
ods, and ranks, we found that the computation cost was min-
imal. For instance, it took up to 8.5 minutes for 100 runs with
the rank of 3 for the leukemia data with 38 patients and 5000
genes (Gaujoux and Seoighe, 2010). We plan to pursue gener-
alizations of this approach, including extensions of our power
prior approach to accommodate other settings, such as sur-
vival endpoints and the inclusion of clinical covariates in the
treatment selection rule. Another future avenue we plan to
pursue is to define an integrative probabilistic framework in
which model-based clustering and treatment assignments are
jointly estimated from the data. This substantial methodolog-
ical development will provide a more flexible and statistically
sound approach as well as circumvent the need to pre-specify
a given clustering approach and rank.
6. Supplementary Materials
Web supplementary sections of A, B, C, and D referenced in
Sections 2–4 as well as R code to implement the proposed
methods are available at the Biometrics Website on Wiley
Online Library.
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